Prognostic Value of Matrix Metalloproteinase 9 in Renal Cell Carcinoma

Черданцева, Т. М.; Бобров, И. П.; Варламов, С. В.; Мяделец, М. Н.; Климачев, И В; Авдалян, А. М.; Ганов, Д И; Лазарев, А. Ф.

doi:10.17650/1726-9776-2018-14-3-17-24

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An individual analysis revealed a decrease in CA9 by 2.5–5.5 times in 70% of the examined patients on the 8–9 th day after the radical operation. These results confirm the existing assumption [ 10 , 13 ] about the predominant production of CA9 by tumor cells.…”

Section: Resultssupporting

confidence: 92%

“…Avdoshin et al [ 17 ] reported differences between urothelial carcinomas of low and high malignancy in terms of expression of MMP9. It should be noted that the decrease in serum MMP9 with increasing tumor sizes or with decreasing tumor differentiation does not corroborate with the expression of MMP9 in tumor cells as reported by others [ 10 ]. Despite the increased proliferation of tumor cells together with MMP9 production, a significant part of MMP9 may still be utilized locally within the malignant cells (for proteolysis of membrane proteins, invasion of tumor cells into the underlying tissues, or neo-angiogenesis) and not reach the bloodstream.…”

Section: Resultscontrasting

confidence: 53%

“…Shchukin et al [ 16 ] showed a correlation between CA9 expression and tumor differentiation (Fuhrman nuclear grade); however, other researchers did not confirm this relationship [ 8 ]. According to some authors [ 10 , 15 ], low expression of CA9 is associated with low cancer-specific survival, overall survival, and progression-free survival.…”

Section: Resultsmentioning

confidence: 99%

“…Matrix metalloproteinases (MMPs) are a family of endopeptidases expressed at various stages of tumor development and involved in the pathways that allow malignant cells to avoid immune response and apoptosis [ 9 , 10 ]. A high level of MMP9 expression was detected in tumor cells in cancer of the lung, bladder, cervix, rectum, prostate, kidney, and the endometrium [ 10 – 12 ]. Yet, we found no reports on correlations between the above marker proteins and clinical and morphological characteristics of RCC, or its response to treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 — Novel Prognostic Markers of Renal Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

The aim of the study was to assess the possibility of using plasma levels of tumor M2-pyruvate kinase (Tu M2-PK), matrix carbonic anhydrase IX (CA9), and matrix metalloproteinase 9 (MMP9) in patients with renal cell cancer as predictors of the disease course and the response to treatment. Materials and Methods. Samples of blood plasma or serum of 46 patients with clear cell renal cancer T 1-4 N 0-1 M 0-1 obtained before surgery and 8-9 days after surgery were tested. The control group consisted of 20 practically healthy individuals, comparable in age with the examined patients. Quantitative determination of Tu M2-PK in EDTA-added blood plasma was performed by enzyme-linked immunosorbent assay using a ScheBo Tumor M2-PK test (Germany). Determination of CA9 by ELISA was performed using a Human Carbonic Anhydrase IX Quantikine ELISA Kit (USA) and MMP9-using a Quantikine ELISA Kit (USA). Results. In patients with renal cell carcinoma, a statistically significant increase in the level of Tu M2-PK, CA9 and a statistically significant decrease in MMP9 in comparison with the control group were found. The level of Tu M2-PK in patients with localized kidney cancer was significantly lower than in patients with disseminated cancer. An increase in size of the primary tumor and a decrease in the degree of its differentiation correlated with an increase in Tu M2-PK, and decrease in CA9 and MMP9 in the blood serum. Performing surgery equivalent to nephrectomy did not change the Tu M2-PK levels in the early postoperative period, but caused a decrease in the levels of CA9 and MMP9. Conclusion. The results indicate a potential significance of Tu M2-PK, CA9, and MMP9 as biological markers for predicting the disease course in patients with renal cell carcinoma.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Resultscontrasting

confidence: 53%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 — Novel Prognostic Markers of Renal Cell Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

Predictive value of MMP-2, MMP-9, TIMP-1 in surgical treatment of localized renal cell cancer

Tarasenko

Россоловский

Березинец

et al. 2021

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Purpose of the study. To determine the association of individual biomolecular markers of oncogenesis MMP‑2, MMP‑9 and the inhibitor of metalloproteinases TIMP‑1 with the risk of tumor invasion and metastasis in the early and late postoperative period in various types of surgical treatment of RCC.Materials and methods. The study prospectively included medical data of 60 patients with kidney cancer with T1-3N0 M0 who received surgical treatment at the Urology Clinic of the S.R.Mirotvortsev Design Bureau of the SSMU from 2016 to 2019. The patients were divided into 3 groups: 1st group included 20 patients who underwent kidney resection for elective indications, with tumors of the renal parenchyma; 2nd group – 20 patients who underwent radical nephrectomy by laparoscopic approach; Group 3-20 patients who underwent radical nephrectomy with lumbotomy access. All patients being in the early (7-10th day) and long-term postoperative period (after 1 and 2 years) by solid-phase ELISA, on a StatFax 4200 analyzer using eBiosence and Cloud-Clone Corp reagent kits, a study was made on the basis of the concentration in the blood serum of markers of oncogenesis MMP‑2, MMP‑9 and TIMP‑1 metalloproteinase inhibitor.Results. In all groups of patients with RCC, an initial increase in the concentration of MMP‑9 was revealed compared to the control (p≤0.05). According to the results of the ROC analysis, this indicator has a high specificity and sensitivity in terms of predicting RCC at the preoperative stage. The highest sensitivity and specificity for detecting tumor progression was demonstrated by matrix metalloproteinases: MMP‑2 – sensitivity 96 %, specificity 67 % (cut-off point 357.5 pg/ml) and MMP‑9 – sensitivity 87.5 % and specificity 62 % (cut-off point 958 ng/ml). At the same time, TIMP‑1 showed less significant indicators – sensitivity and specificity (74 % and 60 %, respectively) with a cut-off point of 0.49 ng/ml.Conclusion. Serum MMP‑2 and MMP‑9 are a marker of a poor prognosis for the progression of RCC. Elevated levels of MMP‑9 in the blood serum of RCC patients before and after various types of surgical treatment reflect the individual characteristics of the patient’s body and the tumor process. Dynamic monitoring of the level of markers of oncogenesis in patients with RCC allows a personalized approach to the choice of the scope and method of surgical treatment of RCC.

show abstract

Prognostic value of matrix metalloproteinases and transforming growth factor – β in kidney cancer

Tarasenko

Rossolovskiy

Березинец

et al. 2022

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Purpose of the study. The study's objective is to investigate the expression level of tissue and serum markers of oncogenesis and nephrofibrosis transforming growth factor beta (TGF‑β) and matrix metalloproteinase‑9 (MMP‑9) in patients operated for various stages of renal cell carcinoma.Materials and methods. The study prospectively included medical data of 60 patients with kidney cancer with T1–3N0M0 who received surgical treatment in the Clinic of Urologynamed after S. R. Mirotvortsev of the State Medical University from 2016 to 2019. The patients were divided into 3 groups: Group 1 included 20 patients who underwent laparoscopic kidney resection; Group 2–20 patients who underwent laparoscopic nephrectomy; Group 3–20 patients who underwent open nephrectomy. The control group consisted of 15 healthy volunteers without chronic kidney diseases. All patients signed an informed consent to participate in the study. All patients at the preoperative stage, in the early (7–10 days) and remote postoperative periods (after 1 and 2 years) were tested by solid‑phase ELISA on a StatFax 4200 analyzer using eBiosence and Cloud‑Clone Corp reagent kits for the serum concentration of oncogenesis markers MMP‑9 and TGF‑β1.Results. Initial increase of MMP‑9 concentration was detected in all groups of PCC patients compared to the control group (p ≤ 0.05). According to the results of ROC analysis, this indicator has high specificity and sensitivity for prognosis of preoperative stage of renal cell carcinoma. The sensitivity and specificity of MMP‑9 were 87.5 % and 62 %, respectively, and the diagnostically significant level of MMP‑9 was 958 ng/ml. A comprehensive analysis of the content of MMP‑9 and TGF‑β1 oncogenesis markers in serum and tumor cells revealed the correlation of these indicators in various biological objects.Conclusion. Markers of oncogenesis and nephrofibrosis TGF‑β1 and MMP‑9 provide an opportunity for non‑invasive monitoring of tumor progression and probability of metastasis in the clinical setting. Serum MMP‑9 are a reliable predictor of tumor growth. Serum TGF‑β1 concentration isn't a sufficiently reliable marker of tumor progression.

show abstract

Prognostic Value of Matrix Metalloproteinase 9 in Renal Cell Carcinoma

Cited by 3 publications

References 9 publications

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 — Novel Prognostic Markers of Renal Cell Carcinoma

Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 — Novel Prognostic Markers of Renal Cell Carcinoma

Predictive value of MMP-2, MMP-9, TIMP-1 in surgical treatment of localized renal cell cancer

Prognostic value of matrix metalloproteinases and transforming growth factor – β in kidney cancer

Contact Info

Product

Resources

About